Combination therapy for cardiovascular diseases
AssigneeThe Brigham and Women's Hospital, Inc.
InventorPaul M. Ridker
Life of this patent
Estimating the term…
Abstract
Provided herein are methods of treating or reducing the risk of a cardiovascular disease using a lipid lowering agent (e.g., statin and/or PCSK9 inhibitor) and an anti-inflammatory agent (e.g., a pro-inflammatory cytokine inhibitor). Further provided herein are methods of predicting the recurrence rate of a subject who has received or is undergoing therapy for a cardiovascular disease with a lipid lowering agent on the basis of the C-reactive protein (CRP) level in the subject. In some embodiments, the recurrence rate can be reduced using an anti-inflammatory agent.
Claims108
A method of treating a cardiovascular disease, the method comprising administering to a subject in need thereof a therapeutically effective amount of a lipid lowering agent and an anti-inflammatory agent.
The method of claim A11 or claim A12, wherein the IL-1R inhibitor is an anti-sense oligonucleotide against IL-1R, anakinra, Rilonacept, MEDI-8968, sIL-1RI, EBI-005, interleukin-1 receptor antagonist (IL-1RA), or AMG108.
A method of reducing a recurrence rate of a cardiovascular disease in a subject who has received or is undergoing therapy with a lipid lowering agent, the method comprising administering to the subject an effective amount of an anti-inflammatory agent.
A method of predicting a recurrence rate of a cardiovascular disease in a subject who has received or is undergoing therapy with the lipid lowering agent, the method comprising measuring a level of C-reactive protein (CRP) in the subject and determining that the subject is likely to have recurrence of the cardiovascular disease if the CRP level is above a pre-determined value.
A method of treating a cardiovascular disease, the method comprising administering to a subject in need thereof a therapeutically effective amount of a bispecific antibody comprising a first antigen-binding domain that binds a proinflammatory cytokine and a second antigen-binding domain that binds a proprotein convertase subtilisin/kexin type 9 (PCSK9).
A method of treating a cardiovascular disease, the method comprising administering to a subject in need thereof a therapeutically effective amount of a bispecific antibody comprising a first antigen-binding domain that binds IL-1 and a second antigen-binding domain that binds a proprotein convertase subtilisin/kexin type 9 (PCSK9).
Dependencies are inferred from the claim text.